

MedMira Inc.

Condensed Interim Consolidated Financial Statements
For the nine months ended April 30, 2023 and April 30, 2022
(Unaudited – Prepared by Management)

In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudited financial statements for the period ending April 30, 2023

June 29, 2023

Management's responsibility for financial reporting

The accompanying consolidated financial statements of MedMira Inc. (MedMira or the Company) are the responsibility of management and have been approved by the Board of Directors. The consolidated financial statements have been prepared by management in accordance with International Financial Reporting Standards (IFRS). The consolidated financial statements includes amounts and assumptions based on management's best estimates which have been derived with careful judgement.

In fulfilling its responsibilities, management has developed and maintains a system of internal accounting controls. These controls are designed to ensure that the financial records are reliable for preparation of the consolidated financial statements.

The Board of Directors of the Company is responsible for ensuring that management fulfils its responsibilities for financial reporting and is ultimately responsible for reviewing and approving the condensed interim consolidated financial statements and the accompanying management's discussion and analysis. The Board of Directors carries out this responsibility principally through its Audit Committee.

The Audit Committee is a subcommittee of the Board of Directors. It is responsible for oversight of the internal control and financial matters assisting the Company's management and independent auditors to ensure that the integrity of the financial reporting process is maintained.

(signed) *Hermes Chan*
Chief Executive Officer

(signed) *Markus Meile*
Chief Financial Officer

Unaudited consolidated statements of financial position
As at April 30, 2023 and July 31, 2022

In Canadian dollars

	Notes	30-Apr-23	31-Jul-22
		\$	\$
Assets			
<i>Current assets</i>			
Cash		83,709	33,461
Trade and other receivables		1,342,175	1,250,088
Income tax receivable		166,182	118,979
Prepaid expenses		45,454	53,933
Inventories	4	<u>178,640</u>	<u>201,964</u>
Total current assets		<u>1,816,160</u>	<u>1,658,425</u>
<i>Non-current assets</i>			
Property, plant and equipment		2,012,710	2,171,146
Intangible assets		<u>2</u>	<u>2</u>
Total non-current assets		<u>2,012,712</u>	<u>2,171,148</u>
Total assets		<u><u>3,828,872</u></u>	<u><u>3,829,573</u></u>
Liabilities			
<i>Current liabilities</i>			
Current portion of debt	8	6,145,445	6,099,672
Trade accounts payable and accrued liabilities		2,843,720	2,749,598
Salaries and benefits payable		1,919,403	1,771,675
Interest payable		2,467,286	2,180,355
Deferred rent		224	15,542
Deferred revenue		772,713	596,713
Provision for royalty	10	72,673	72,673
Advance from shareholder		500,000	500,000
Current portion of lease liabilities	7	<u>164,268</u>	<u>151,526</u>
Total current liabilities		<u>14,885,732</u>	<u>14,137,754</u>
<i>Long term liabilities</i>			
Long term debt	8	1,127,117	40,000
Lease liability	7	<u>1,884,959</u>	<u>2,007,816</u>
Total long term liabilities		<u>3,012,076</u>	<u>2,047,816</u>
Total liabilities		<u>17,897,808</u>	<u>16,185,570</u>
Equity			
Share capital	5	68,349,720	68,349,720
Equity reserve	5	14,577,728	14,577,728
Accumulated deficit		<u>(96,996,384)</u>	<u>(95,283,445)</u>
Total shareholders' deficiency		<u>(14,068,936)</u>	<u>(12,355,997)</u>
Total liabilities and equity		<u><u>3,828,872</u></u>	<u><u>3,829,573</u></u>

The accompanying notes are an integral part of these consolidated financial statements.

Approved on behalf of the Board of Directors

(signed) *Hermes Chan*, Director

(signed) *Steve Cummings*, director

Unaudited consolidated statements of operations and comprehensive loss
For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

	<i>Notes</i>	for the three months ended		for the nine months ended	
		30-Apr-23	30-Apr-22	30-Apr-23	30-Apr-22
		\$	\$	\$	
Product					
Product sales	3	62,681	110,930	220,931	254,276
Product cost of sales		<u>(10,090)</u>	<u>(14,332)</u>	<u>(32,734)</u>	<u>(47,395)</u>
Gross margin on product		<u>52,591</u>	<u>96,598</u>	<u>188,197</u>	<u>206,881</u>
Service					
Service sales	3	43,329	212,995	176,387	569,295
Service costs of sales		<u>(34,663)</u>	<u>(212,995)</u>	<u>(115,123)</u>	<u>(569,295)</u>
Gross margin on Service		<u>8,666</u>	<u>-</u>	<u>61,264</u>	<u>-</u>
Operating expenses					
Research and development	12	(96,789)	(36,319)	(392,063)	(70,635)
Sales and marketing		(177,369)	(3,515)	(193,270)	(3,745)
Other direct costs		(164,299)	(184,872)	(551,041)	(629,548)
General and administrative		<u>(255,216)</u>	<u>(167,782)</u>	<u>(613,199)</u>	<u>(547,488)</u>
Total operating expenses		<u>(693,673)</u>	<u>(392,488)</u>	<u>(1,749,573)</u>	<u>(1,251,416)</u>
Operating loss		<u>(632,416)</u>	<u>(295,890)</u>	<u>(1,500,112)</u>	<u>(1,044,535)</u>
Non-operating income (expenses)					
Government Assistance		166,182	-	166,182	64,703
Financing		<u>(123,748)</u>	<u>(115,177)</u>	<u>(379,009)</u>	<u>(388,585)</u>
Net (loss) income		<u>(589,982)</u>	<u>(411,067)</u>	<u>(1,712,939)</u>	<u>(1,368,417)</u>
Basic (loss) earnings per share	6	(0.0008)	(0.0006)	(0.0025)	(0.0020)
Diluted (loss) earnings per share	6	(0.0008)	(0.0006)	(0.0025)	(0.0020)

The accompanying notes are an integral part of these consolidated financial statements.

Unaudited consolidated statements of changes in equity
In Canadian dollars

	<i>Notes</i>	Common shares	Preferred shares	Warrant reserve	Equity reserve	Accumulated deficit	Shareholders' deficiency
Balance at July 31, 2021		63,901,590	2,500	31,961	13,791,920	(93,451,869)	(15,723,898)
Net and comprehensive net loss		-	-	-	-	(1,368,417)	(1,368,417)
Shares issued for cash		911,844	-	753,847	-	-	1,665,691
Shares issued for debt		3,564,437	-	-	-	-	3,564,437
Share issuance costs		(30,651)	-	-	-	-	(30,651)
Expiration of warrants		-	-	(31,961)	31,961	-	-
Balance at April 30, 2022		68,347,220	2,500	753,847	13,823,881	(94,820,286)	(11,892,838)
Net and comprehensive loss		-	-	-	-	(463,159)	(463,159)
Shares issued for cash	5	-	-	-	-	-	-
Shares issued for debt	5	-	-	-	-	-	-
Expiration of warrants	5	-	-	(753,847)	753,847	-	-
Share issuance costs	5	-	-	-	-	-	-
Balance at July 31, 2022		68,347,220	2,500	-	14,577,728	(95,283,445)	(12,355,997)
Net and comprehensive income		-	-	-	-	(1,712,939)	(1,712,939)
Balance at April 30, 2023		68,347,220	2,500	-	14,577,728	(96,996,384)	(14,068,936)

The accompanying notes are an integral part of these consolidated financial statements.

Unaudited consolidated statements of cash flows
For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

	<i>Notes</i>	30-Apr-23 \$	30-Apr-22 \$
Cash from operating activities			
Net loss		(1,712,939)	(1,368,417)
Adjustments for:			
Depreciation		159,703	159,124
Movements in working capital:			
Increase in trade and other receivables		(92,087)	51,108
Decrease in inventories		23,324	351
Increase (decrease) in prepaid expenses		8,479	47,494
Decrease in income tax receivable		(47,203)	-
Increase (decrease) in trade accounts payable and accrued liabilities		94,122	(129,531)
Increase in other current liabilities		419,341	(246,169)
Increase (decrease) in deferred revenue		176,000	(579,705)
Net cash used in operating activities		<u>(971,260)</u>	<u>(2,065,745)</u>
Cash flow from investing activities			
Payments to acquire financial assets		(1,267)	(69,717)
Net cash used in investing activities		<u>(1,267)</u>	<u>(69,717)</u>
Cash flow from financing activities			
Decrease in bank indebtedness		-	(10,113)
Share issuance	5		2,111,913
Share issuance costs	5	-	(30,651)
Decrease in lease obligations	7	(110,115)	(90,392)
Advance from shareholder		-	500,000
Proceeds from borrowings	8	1,117,890	55,847
Repayment of borrowings	8	15,000	(5,000)
Net cash from financing activities		<u>1,022,775</u>	<u>2,531,604</u>
Net increase (decrease) in cash		50,248	396,142
Cash at the beginning of the year		33,461	-
Cash at the end of the year		<u>83,709</u>	<u>396,142</u>

The accompanying notes are an integral part of these consolidated financial statements.

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

1. Reporting entity

Nature of operations

MedMira Inc. (“MedMira” or “the Company”) is a biotechnology company headquartered in Canada. The address of the Company’s registered office is 155 Chain Lake Drive, Suite 1, Halifax, Nova Scotia, B3S 1B3. MedMira Holding AG owns the majority of MedMira’s shares and is the controlling shareholder. MedMira, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research in order to maintain and expand its position in the global diagnostics market. MedMira’s research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and *in vitro* sectors.

2. Basis of preparation

a. Statement of compliance

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”).

The consolidated financial statements were authorized for issue by the Board of Directors on June 29, 2023.

b. Going-concern

The accompanying consolidated financial statements have been prepared on the basis of IFRS applicable to a going-concern, which contemplates the realization of assets and liquidation of liabilities during the normal course of operations. However, certain adverse conditions and events cast significant doubt upon the validity of this assumption.

The Company has incurred losses and negative cash flows from operations on a cumulative basis since inception. For the nine months ended April 30, 2023, the Company realized a net loss of \$1.7 million (April 30, 2022 – net loss of \$1.4 million), consisting of a net loss from operations of \$1.5 million (April 30, 2022 – net loss \$1.0), and other non-operating losses of \$0.2 million (April 30, 2022 - \$0.4 million). Negative cash inflows from operations were \$1.0 million (April 30, 2022 – net outflows of \$2.1 million). As at April 30, 2023, the Company had an accumulated deficit of \$97.0 million (July 31, 2022 - \$95.3 million) and a negative working capital position of \$13.1 million (July 31, 2022 - \$12.5 million). In addition, as of April 30, 2023, \$6.0 million of debt was in default. The Company currently has insufficient cash to fund its operations for the next 12 months. In addition to its ongoing working capital requirements, the Company must secure sufficient funding for its research and development programs for existing commitments, including its current portion of debt of approximately \$6.0 million. These material uncertainties may cast significant doubt about the Company’s ability to continue as a going concern.

The Company’s objectives in managing capital are to ensure it can meet its ongoing working capital requirements. The Company must secure sufficient capital to support its capital requirements for research and development programs, existing commitments, including its current portion of debt of approximately \$6.0 million, as well as growth opportunities.

Management dedicates significant time to pursuing investment alternatives that will fund the Company’s operations and growth opportunities so it can continue as a going concern. Debt arrangements were also ongoing with the Company’s major shareholder and other debt holders. Subsequent to the close of the second quarter of fiscal year

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

2023, the Company, has generated additional revenues from product sales, product development and license fees, which support the Company's on-going operating costs and provide funding for its product development activities. Management continues to work closely with its main investor to support any additional cash requirements if needed, nevertheless there is no assurance that this initiative would be successful.

The Company is subject to risks associated with early stage companies, including but not limited to, dependence on key individuals, competition from substitute services and larger companies, and the requirement for the continued successful development and marketing of its products and services. The Company's ability to continue as a going-concern is dependent upon its ability to generate positive cash flow from operations and secure additional financing and the continued support of its lenders and shareholders. These financial statements do not reflect the adjustments to carrying values of assets and liabilities and the reported expenses and statement of financial position classifications that would be necessary were the going-concern assumption not appropriate. These adjustments could be material.

c. Basis of consolidation

Subsidiaries

Subsidiaries are entities controlled by the Company. Control is achieved when the Company has the power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee; and has the ability to use its power to affect its returns. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there changes to one or more of the three elements of control listed above. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Intra-company balances and transactions, and any unrealized income and expenses arising from intra-company transactions, are eliminated in preparing the consolidated financial statements.

3. Revenue

The Company derives approximately 87% (April 30, 2022 – 87%) of its revenue from three (April 30, 2022 — three) main customers and, for these customers, assesses the recoverability of each account on a regular basis. During the nine months ended April 30, 2023, customer 1 accounted for 44% of the Company's revenue, customer 2 accounted for 22% of the revenue, and customer 3 accounted for 21%.

The Company organizes and records revenue based on major geographical territories around the world. The table below provides the geographic breakdown of revenue.

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

	for the three months ended		for the nine months ended	
	30-Apr-23	30-Apr-22	30-Apr-23	30-Apr-22
			\$	\$
North America	103,942	310,673	377,099	803,545
Asia Pacific	-	-		454
Europe	2,068	13,252	20,219	19,572
Total revenue	106,010	323,925	397,318	823,571

*For the three months ended April 30, 2023, revenue in North America included sales made in Canada (the Company's country of domicile) of \$11,689 (April 30, 2022 - \$9,505).

4. Inventories

As at April 30, 2023, there were no valuation allowances against inventory (July 31, 2022 - \$nil).

During the nine months ended April 30, 2023, inventory valued at \$35,113 was expensed as product cost of sales (April 30, 2022 - \$23,946), which included write-downs of inventory as a result of net realizable value being lower than cost of \$6,361 (April 30, 2022 - \$4,776). No inventory write-downs recognized in previous years were reversed during the current year.

	30-Apr-23	31-Jul-22
	\$	\$
Raw materials and consumables	160,928	175,169
Work in process	10,846	18,111
Finished goods	6,866	8,684
Total inventories	178,640	201,964

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

5. Capital and other components of equity

a. Authorized

The Company is authorized to issue an unlimited number of Series A preferred shares, non-voting, non-participating, redeemable at the Company's option at \$0.001 per share after March 31, 2010, convertible into an equal number of common shares upon the Company meeting certain milestones. The preferred shares earn no dividends.

The Company is authorized to issue an unlimited number of voting common shares without nominal or par value.

b. Share capital issued

	Number of		Value of		Total share capital
	Common shares	Preferred shares	Common shares	Preferred shares	
Balance at July 31, 2022	697,445,660	5,000,000	\$ 68,347,220	\$ 2,500	\$ 68,349,720
Balance at April 30, 2023	697,445,660	5,000,000	68,347,220	2,500	68,349,720

The total common shares issued and outstanding includes 4,064,464 common shares held in escrow scheduled to be released when the Company obtains positive operating cash flow.

The Series A preferred shares had a stated capital of \$2,500 at April 30, 2023 (July 31, 2022 - \$2,500).

c. Equity Reserve

The change in equity reserve is outlined in the table below:

	Equity Reserve
Balance at July 31, 2022	\$ 14,577,728
Balance at April 30, 2023	14,577,728

In Canadian dollars

6. Loss per share

	For the three months ended		For the nine months ended	
	30-Apr-23	30-Apr-22	30-Apr-23	30-Apr-22
			\$	\$
Net income (loss) attributable to common shareholders	(589,982)	(411,067)	(1,712,939)	(1,368,417)
Issued common shares	697,445,660	697,445,660	697,445,660	697,445,660
Weighted average number of common shares	697,445,660	697,445,660	697,445,660	697,445,660
Basic earnings (loss) per share	(0.0008)	(0.0006)	(0.0025)	(0.0020)
Diluted earnings (loss) per share	(0.0008)	(0.0006)	(0.0025)	(0.0020)

The diluted weighted average number of common shares outstanding is the same as the basic weighted average number of common shares outstanding for the three and six months ended April 30, 2023, as the exercise of options would be anti-dilutive.

7. Lease liability

	Building
	\$
at July 31, 2022	2,159,342
Interest expense	80,975
Less: Lease payments	<u>(191,090)</u>
at April 30, 2023	2,049,227
Less: Current portion	<u>(164,268)</u>
	1,884,959

In Canadian dollars

The lease liability is based on one lease the company has for the building it is using for operations. The remaining lease term is six months with an option to renew for two additional terms of five years each. The imputed finance costs of the liability was determined based on an incremental borrowing rate of 5%. The minimum lease payments for the next five year are as follows:

		Lease Liability \$	Finance Charge \$	Total \$
Twelve months ending April 30	2024	164,268	102,285	266,553
	2025	176,541	94,046	270,587
	2026	185,355	85,232	270,587
	2027	201,683	75,964	277,647
	2028	215,826	65,855	281,681

8. Loans and borrowings

a. Loans

	<u>30-Apr-23</u>		<u>31-Jul-22</u>	
	Carrying value \$	Contract value \$	Carrying value \$	Contract value \$
Short term loans	158,430	158,430	153,335	153,335
Loan 1	1,054,167	1,054,167	1,054,167	1,054,167
Loan 2	1,300,000	1,300,000	1,300,000	1,300,000
Loan 3	5,849	5,848	5,170	5,170
Loan 4	75,000	75,000	-	-
Loan 5	75,000	75,000	-	-
Loan 6	203,670	203,670		
Loan 7	304,120	304,120		
Loan 8	152,060	152,060		
Loan 9	167,266	167,266		
Loan 10	150,000	150,000		
Canada emergency business account	40,000	40,000	40,000	40,000
ACOA loans	473,610	473,610	473,610	473,610
Nova Scotia government loan 1	3,016,000	3,016,000	3,016,000	3,016,000
Nova Scotia government loan 2	97,390	97,390	97,390	97,390
Total loan principal	<u>7,272,562</u>	<u>7,272,561</u>	<u>6,139,672</u>	<u>6,139,672</u>
Long term portion of principal	1,127,117		40,000	
Current portion payable of principal	6,145,445		6,099,672	

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

The required annual principal repayments on loans and borrowings are as follows:

	Repayment required
	\$
Fiscal year 2023	6,105,445
Fiscal year 2024	40,000
Fiscal year 2025	1,127,117
Total	7,272,562

Short term loans

The Company has one short term loan with one related party. The loan is utilized by the Company for short term working capital requirements. This loan has an interest rate of 5% per year. As of April 30, 2023, the loan is in default due to non-payment.

Loan 1

Loan established October 31, 2012, bearing 5% interest with monthly interest only payments until November 30, 2013, followed by monthly principal payments and accrued interest for five additional years ending November 30, 2018. The loan is secured by interest on intellectual property and on the step-up technology. The loan was in default on April 30, 2023 due to non-payment of principal and interest and thus has been classified as a current liability.

Loan 2

Loan established July 31, 2012, bearing 5% interest with monthly interest payments were due until April 30, 2016, followed by equal monthly principal payments and accrued interest for four additional years ending July 31, 2020. The loan was in default on April 30, 2023 due to non-payment of principal and interest and thus has been classified as a current liability.

Loan 3

Loan was established on July 31, 2016, bearing 5% interest with the Company's Chief Financial Officer. The loan was renegotiated on January 21, 2017 and is now fully payable on or before October 1, 2019. The loan was in default on April 30, 2023 due to non-payment of principal and interest and thus has been classified as a current liability.

Loan 4

Loan was established on August 18, 2022, bearing 5% interest. The loan is due on January 31, 2025.

Loan 5

Loan was established on August 18, 2022, bearing 5% interest. The loan is due on January 31, 2025.

Loan 6

Loan was established on August 18, 2022, bearing 5% interest. The loan is due on January 31, 2025.

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

Loan 7

Loan was established on December 19, 2022, bearing 5% interest. The loan is due on December 1, 2024.

Loan 8

Loan was established on April 4, 2023 bearing 5% interest. The loan is due on April 4, 2025.

Loan 9

Loan was established on February 23, 2023 bearing 5% interest with the company's largest shareholder. The loan is due on February 23, 2025.

Loan 10

Loan was established on April 21, 2023 bearing 5% interest. The loan is due on April 21, 2025.

Canada Emergency Business Account (CEBA)

The Company received a loan of CAD\$40,000 from Bank of Montreal which is fully secured by the Government of Canada. This Relief Line of Credit was the governments direct response to support Canadian companies during the COVID-19 situation. This loan carries an interest rate of 0% per annum to be repaid in full by the December 31, 2023. This loan may be extended from January 1, 2024 to December 31, 2026 in which case this loan carries an interest of 5%. If this loan is repaid before December 31, 2023 the Company is entitled to a credit in the amount of 25% equal to \$10,000.

Atlantic Canada Opportunities Agency (ACOA) loans

Loans established on October 31, 2012, bearing no interest with monthly principal payments of \$3,747 until July 31, 2013, followed by monthly principal payments of \$24,234 for five additional years ending July 31, 2018. The loan was renegotiated in July 2014, bearing no interest with a monthly principal payment of \$24,234 in August 2014 followed by 40 monthly principal payments of \$27,800 starting on February 1, 2015 and one monthly principal payment of \$26,975 at the end of the loan. The loan is secured by all present and subsequently acquired personal property, excepting consumer goods. The loan was in default on April 30, 2023 due to non-payment of principal and interest and thus has been classified as a current liability.

Nova Scotia government loan 1

The loan was established in August 2015, bearing interest based on the Province of Nova Scotia's five year cost of funds, plus five hundred basis points. Monthly interest payments are due until August 31, 2018. Starting on September 1, 2016, thirteen monthly principal payments of \$120,000 are due followed by ten monthly principal payments of \$135,000 starting on October 1, 2017 and one monthly principal payment of \$106,000 on August 1, 2018. The loan is secured by first interest on intellectual property and on the Maple Bio sensor technology. The loan was in default due to nonpayment of interest and principal payments at April 30, 2023 and thus has been classified as a current liability. In September 15, 2020 the Company has entered into a forbearance agreement with the Province of Nova Scotia which allows the Company to defer principal and interest payments. The terms and condition were based on the Company's growth and milestone based achievements. On April 4, 2022, the Company received an additional forbearance extension for a period of twelve months. Pending on the Company's achievement of growth milestones, the Province may extend this further.

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

Nova Scotia government loan 2

Loan established September 14, 2012, bearing no interest with the balance due by August 31, 2018. The loan is secured by first interest on intellectual property and on the Maple Bio sensor technology. The loan was in default due to nonpayment of interest and principal payments at April 30, 2023, 2022 and thus has been classified as a current liability. In September 15, 2020 the Company has entered into a forbearance agreement with the Province of Nova Scotia which allows the Company to defer principal and interest payments. The terms and condition were based on the Company's growth and milestone based achievements. On April 4, 2022, the Company received an additional Forbearance extension for a period of twelve months. Pending on the Company's achievement of growth milestones, the Province may extend this further.

9. Capital management and financial risks

a. Capital management

The Company's objectives in managing capital are to ensure sufficient liquidity to support the capital requirements of its various businesses, including growth opportunities. The Company manages its capital structure and makes adjustments in light of general economic conditions, the risk characteristics of the underlying assets and the Company's working capital requirements. Management of the capital structure involves the issuance of new debt, the repayment of existing debt using cash generated by operations and issuance of additional financial structures such as product financing and royalty agreements. The capital structure of the Company is composed of shareholders' deficiency, cash, long-term and short-term debts. The provisions of certain financing agreements provide for restrictions on the activities of the Company in terms of their use of funds. Such restrictions are mainly applied in specific product development financing projects. The Company's objectives when managing capital are to provide competitive cost structures, safeguard its assets and daily cash flow management in order to maximize the Company's cash holding.

The Company's capital is summarized in the table below.

	\$	\$
Total debt	7,272,562	6,139,672
Less: Cash	<u>(83,709)</u>	<u>(33,461)</u>
Net debt	7,188,853	6,106,211
Shareholders' deficiency	<u>(14,068,936)</u>	<u>(12,355,997)</u>
Total capital	<u>(6,880,083)</u>	<u>(6,249,786)</u>

Refer to the note 2b for information on how the Company manages its plan and its ability to continue as a going concern.

b. Foreign currency risk

Most of the Company's sales are denominated in foreign currencies. The Company's US dollar foreign currency denominated monetary assets and monetary liabilities at the end of the reporting period are shown in the table below.

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

	30-Apr-23	31-Jul-22
	US\$	US\$
Cash	182	6,969
Trade and other receivables	929,959	916,813
Prepays	280	280
Accounts payable and accrued liabilities	1,403,608	1,283,607
Royalty provision	61,547	56,670
Debt	150,000	-

A one percent change in the US dollar exchange rate would result in approximately a \$25,456 (July 31, 2022 - \$22,643) impact on the statement of financial position and consolidated statement of operations.

The Company's Swiss Franc foreign currency denominated monetary assets and monetary liabilities at the end of the reporting period are shown in the table below:

	30-Apr-23	31-Jul-22
	CHF	CHF
Cash	9,120	17,146
Trade and other receivables	2,048	2,753
Prepays	17,903	-
Accounts payable and accrued liabilities	382,978	375,322
Debt	518,036	117,900

A one percent change in the US dollar exchange rate would result in approximately a \$9,301 (July 31, 2022 - \$5,131) impact on the statement of financial position and consolidated statement of operations.

c. Interest rate risk

The Company is not exposed to interest rate risk as it borrows funds at fixed rates.

d. Credit risk

The Company exposed to credit risk in relation to its trade accounts receivable. To mitigate such risk, the Corporation continuously monitors the financial condition of its customers and reviews the credit history or worthiness of each new customer. The Company mitigates this risk by requiring a 100% down payment prior to shipment for new clients. The Company establishes an allowance for doubtful accounts based on specific credit risk of its customers by examining such factors as the number of overdue days of the customers' balance outstanding as well as the customers' collection history. Since 86% of the Company's sales are with four international companies there is no significant concentration of credit risk.

Trade and other receivables include amounts that are past due as of April 30, 2023, for which the Company has not recognized an allowance for doubtful accounts because there has not been a significant change in the credit quality of the customer and the amounts are still considered recoverable.

e. Liquidity risk

Liquidity risk represents the possibility that the Company may not be able to gather sufficient cash resources, when required and under reasonable conditions, to meet its financial obligations. As at April 30, 2023, the Company does not have sufficient cash to meet all of its current liabilities.

The Company also continues to have an ongoing need for substantial capital resources to research and develop, commercialize and manufacture its products and technologies. The Company is not yet receiving a significant ongoing revenue stream, nor can it be certain that it will receive significant revenue before additional cash is required. As a result, there can be no assurance that the Company will have sufficient capital to fund its ongoing operations, develop or commercialize its products without future financing.

The Company's contractual maturities for its financial liabilities are outlined in the table below.

For the nine months ended April 30, 2023

	Total \$	Less than 1 year \$	1 to 3 years \$	4 to 5 years \$	After 5 years \$
Debt	7,272,562	6,145,445	1,127,117	-	-
Accounts payable and accrued liabilities	7,230,409	7,230,409	-	-	-
Lease liabilities	2,049,227	164,268	563,578	442,430	878,951
Advance from shareholder	500,000	500,000	-	-	-
Royalty provision	72,673	72,673	-	-	-
Total debt	17,124,871	14,112,795	1,690,695	442,430	878,951

For the year ended July 31, 2022

	Total \$	Less than 1 year \$	1 to 3 years \$	4 to 5 years \$	After 5 years \$
Debt	6,139,672	6,099,672	40,000	-	-
Accounts payable and accrued liabilities	6,701,628	6,701,628	-	-	-
Advance from shareholder	500,000	500,000	-	-	-
Lease liabilities	2,159,342	151,526	535,432	425,467	1,046,917
Royalty provision	72,673	72,673	-	-	-
Total debt	15,573,315	13,525,499	575,432	425,467	1,046,917

The payments noted above do not include interest payments.

10. Royalty provision

During March 2015, the Company entered into a royalty agreement with MedMira Holding AG whereby MedMira Holding AG would receive a 10% royalty on all future US sales of the Reveal G4 product for a five year period commencing on the day the first full payment and delivery of at least CAD \$100,000 worth of product. In exchange, MedMira Holding AG provided the Company with \$270,000 to fund costs required to complete the product development and obtain US Food and Drug Administration (FDA) pre-market approval. At the inception of the arrangement, the Company's best estimate of the value of the provision was zero and as MedMira Holding AG is the controlling shareholder of the Company, the \$270,000 was recorded in equity (Note 8). As at April 30, 2023, the Company's best estimate of the fair value of the provision was \$72,673 (July 31, 2022 - \$72,673), which is recorded in royalty provision and the change in fair value of the provision recorded in financing expense in profit or loss.

MedMira Inc.

Notes to the Consolidated Financial Statements

For the nine months ended April 30, 2023 and April 30, 2022

In Canadian dollars

During July 2016, the Company entered into a royalty agreement with MedMira Holding AG whereby MedMira Holding AG would receive a 10% royalty on all future sales of the hepatitis C (HCV) portion of the approved Multiplo HIV/HCV test commencing on the day of the first full delivery and payment of CAD \$10,000 worth of product. In exchange, MedMira Holding AG provided the Company with \$200,000 to fund costs required to complete product development and obtain FDA pre-market approval. At the inception of the arrangement, the Company's best estimate of the fair value of the provision was zero and as MedMira Holding AG is the controlling shareholder of the Company, the \$200,000 was recorded in equity reserve. As at April 30, 2023, the Company's best estimate of the fair value of the provision was zero. Management's fair value estimate was based on changes made during the FY2017 product commercialization prioritization process which placed the Multiplo HIV/HCV project on hold until further notice.

During October 2016, the Company entered into a royalty agreement with Ritec AG whereby Ritec AG would receive a 12.5% royalty on all future sales of the approved Reveal G4 CLIA-waived product commencing on the day of the first full delivery and payment of CAD \$10,000 worth of product. In exchange, Ritec AG provided the Company with \$1,310,100 to fund costs required to complete the product development, clinical trials and obtain FDA approval. At the inception of the arrangement, the Company's best estimate of the fair value of the provision was zero and as Ritec AG is owned by a shareholder of MedMira Holding AG who is the controlling shareholder of the Company, the \$1,310,100 was recorded in equity reserve. At April 30, 2023, the Company's best estimate of the fair value of the provision was zero.

The change in royalty provision is outlined in the table below:

	\$
Balance at July 31, 2022	72,673
Balance at April 30, 2023	72,673

11. Related parties

The following transactions occurred with related parties during the year ended April 30, 2023

- Two long term loans of \$471,386 were received from Urs Meile (2022 – nil)

The following balances with related parties were outstanding at April 30, 2023:

- Salaries and benefits payable totalling \$1,353,178 was due to the CEO and CFO (2022 - \$1,232,784).
- A long term loan totalling \$5,848 (2022 - \$5,170) and accrued interest of \$429 (2022 - \$186) was due to the Chief Financial Officer.
- A short term loan totalling \$158,430 (2022-\$153,334) and accrued interest of \$27,386 (2022 - \$18,893) were owed to the Chief Financial Officer
- A royalty provision was owed to MedMira Holding AG of \$72,673 (2022 - \$72,673).
- A long term loan totalling \$471,386 (2022 – nil) and accrued interest of \$6,920 (2022 – nil) was owed to Urs Meile.

12. Research and development

The following table provides a summary of aggregate research costs and reimbursements.

	for the three months ended		for the six months ended	
	30-Apr-23	30-Apr-22	30-Apr-23	30-Apr-22
	\$	\$	\$	\$
Research and development (R&D) expenses	(114,576)	(203,777)	(458,775)	(401,703)
Less: R&D allocated to cost of sales	17,787	167,458	66,712	331,068
Net research and development expense	(96,789)	(36,319)	(392,063)	(70,635)

13. Expenses by nature

The following table provides the Company's expenses listed by the nature of the expense.

	for the three months ended		for the nine months ended	
	30-Apr-23	30-Apr-22	30-Apr-23	30-Apr-22
	\$	\$	\$	\$
Change in inventory	(10,468)	(10,292)	(35,113)	(302,248)
Employee benefits	(311,949)	(340,371)	(927,710)	(1,079,963)
Depreciation	(53,234)	(53,171)	(159,703)	(155,031)
Distribution	(652)	(18,021)	(8,129)	(29,330)
Facility	(43,791)	(27,252)	(78,379)	(143,232)
Professional services	(201,318)	(17,799)	(351,371)	(80,329)
Lab supplies	(17,665)	(1,824)	(76,052)	(98,713)
Other expenses	(32,730)	(163,062)	(129,230)	(173,356)
Exchange gains (losses)	(66,619)	11,977	(131,740)	455,560
Finance costs	(123,748)	(115,177)	(379,012)	(486,302)
Government Assistance	166,182	-	166,182	20,000
	(695,992)	(734,992)	(2,110,257)	(2,072,944)

14. Financing expense

A breakdown of the income (expenses) allocated to financing expense on the consolidated statements of operations and comprehensive loss is provided in the table below.

	for the three months ended		for the nine months ended	
	30-Apr-23	30-Apr-22	30-Apr-23	30-Apr-22
	\$	\$	\$	\$
Finance costs	(123,748)	(115,177)	(379,009)	(388,585)
Government Assistance	166,182	-	166,182	-
Gain on Emergency Business account loan	-	-	-	64,703
Total financing expense	42,434	(115,177)	(212,827)	(323,882)